CC BY-NC-ND 4.0 · South Asian J Cancer 2022; 11(02): 160-163
DOI: 10.1055/s-0041-1739179
Original Article
Pediatric Cancer

Retinoblastoma Outcomes in a Tertiary Hospital in Northern Luzon, The Philippines: A 15-Year Experience

Roland Joseph D. Tan
1   Department of Ophthalmology, Baguio General Hospital and Medical Center, Baguio City, Philippines
2   Department of Ophthalmology and Visual Sciences, Philippine General Hospital, Manila, Philippines
3   College of Medicine, University of the Philippines, Manila, Philippines
,
Kathleen Faye B. Ballesteros
1   Department of Ophthalmology, Baguio General Hospital and Medical Center, Baguio City, Philippines
› Author Affiliations
Funding No financial support received for the research, authorship, and publication of this article.

Abstract

Zoom Image
Roland Joseph D. Tan

Objective To describe the demographics, clinical profile, and outcomes of retinoblastoma patients seen in a tertiary hospital in northern Luzon.

Materials and Methods This is a retrospective cross-sectional study of retinoblastoma patients at the departments of ophthalmology and pediatrics of a tertiary hospital in northern Luzon from 2005 to 2020.

Results A total of 47 patients involving 53 eyes were included. Twenty nine (62%) are male and forty one (87%) had unilateral retinoblastoma. Mean age at consult was 24 ± 17 months, and mean interval from onset of symptoms to consult was 10 ± 11 months. Two (4%) had family history of retinoblastoma. Twenty-two (47%) patients had intraocular involvement. Leukocoria was the most common presenting symptoms at 62%. Overall survival was 53% with mean follow-up period of 24 ± 24 months. Difference in survival rates based on the extent of involvement was statistically significant (p < 0.001).

Conclusion This is the first study that provided data on demographics, clinical profile, and outcomes of retinoblastoma patients in northern Luzon and the only study with data on clinical outcomes of retinoblastoma patients in The Philippines. Extraocular involvement is a significant factor in the low survival of retinoblastoma patients despite improvement in its management.

Author Contribution

The authors equally contributed to the conceptualization, writing, and final approval of this manuscript.


Ethical Approval

This study was approved by the Baguio General Hospital and Medical Center Research Ethics Committee (REC-2020–29) and adhered to the Declaration of Helsinki.


Note

An earlier version of this paper was poster presented in the Asia Pacific Society of Pediatric Ophthalmology and Strabismus Inaugural Congress at Hong Kong, China, on October 2017.




Publication History

Article published online:
22 March 2022

© 2022. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 
  • References

  • 1 Seregard S, Lundell G, Svedberg H, Kivelä T. Incidence of retinoblastoma from 1958 to 1998 in Northern Europe: advantages of birth cohort analysis. Ophthalmology 2004; 111 (06) 1228-1232
  • 2 Jerry and Carol Shields's Management and Prognosis of Retinoblastoma. In: Atlas of Intraocular Tumors. Philadelphia: Lippincott Williams & Wilkins; 1999
  • 3 Fabian ID, Reddy A, Sagoo MS. Classification and staging of retinoblastoma. Community Eye Health 2018; 31 (101) 11-13
  • 4 Shields CL, Mashayekhi A, Au AK. et al. The International Classification of Retinoblastoma predicts chemoreduction success. Ophthalmology 2006; 113 (12) 2276-2280
  • 5 Jain M, Rojanaporn D, Chawla B, Sundar G, Gopal L, Khetan V. Retinoblastoma in Asia. Eye (Lond) 2019; 33 (01) 87-96
  • 6 Noguerra SI, Mercado GJV, Santiago DE. Clinical epidemiology of retinoblastoma at the Philippine General Hospital: 1998–2008. Philipp J Ophthalmol 2011; 36 (01) 28-32
  • 7 Chantada G, Doz F, Antoneli CB. et al. A proposal for an international retinoblastoma staging system. Pediatr Blood Cancer 2006; 47 (06) 801-805
  • 8 Fabian ID, Sagoo MS. Understanding retinoblastoma: epidemiology and genetics. Community Eye Health 2018; 31 (101) 7
  • 9 Stiller CA, Parkin DM. Geographic and ethnic variations in the incidence of childhood cancer. Br Med Bull 1996; 52 (04) 682-703
  • 10 Espiritu RB, de Jesus AA, Valera EG, Mercado GJ. Epidemiological pattern of retinoblastoma at the Philippine General Hospital. Philipp J Ophthalmol 2004; 29: 136-139
  • 11 Usmanov RH, Kivelä T. Predicted trends in the incidence of retinoblastoma in the Asia-Pacific region. Asia Pac J Ophthalmol (Phila) 2014; 3 (03) 151-157
  • 12 Fabian ID, Abdallah E, Abdullahi SU. et al; Global Retinoblastoma Study Group. Global retinoblastoma presentation and analysis by national income level. JAMA Oncol 2020; 6 (05) 685-695
  • 13 Asih D, Gatot D, Sitorus R. Computed tomography findings of retinoblastoma patients at Cipto Mangunkusumo Hospital Jakarta. Med J Indones 2009; 18 (04) 239
  • 14 Shah PK, Narendran V, Kalpana N. Outcomes of intra- and extraocular retinoblastomas from a single institute in south India. Ophthalmic Genet 2015; 36 (03) 248-250
  • 15 Chawla B, Hasan F, Seth R. et al. Multimodal therapy for stage III retinoblastoma (International Retinoblastoma Staging System): a prospective comparative study. Ophthalmology 2016; 123 (09) 1933-1939
  • 16 Singh G, Daniels AB. Disparities in retinoblastoma presentation, treatment, and outcomes in developed and less-developed countries. Semin Ophthalmol 2016; 31 (04) 310-316
  • 17 Kaliki S, Patel A, Iram S, Ramappa G, Mohamed A, Palkonda V. Retinoblastoma in India. Retina 2019; 39 (02) 379-391
  • 18 Bakhshi S, Gupta S, Gogia V, Ravindranath Y. Compliance in retinoblastoma. Indian J Pediatr 2010; 77 (05) 535-540
  • 19 Siddiqui S, Shaikh Z, Ahmed J. Retinoblastoma: clinical picture and grouping at the time of first presentation. Pakistan Journal of Medical Science Online 2011;27(05):
  • 20 Adhi MI, Kashif S, Muhammed K, Siyal N. Clinical pattern of retinoblastoma in Pakistani population: review of 403 eyes in 295 patients. J Pak Med Assoc 2018; 68 (03) 376-380
  • 21 Khan A, Bukhari M, Mehboob R. Association of retinoblastoma with clinical and histopathological risk factors. Nat Sci 2013; 05 (04) 437-444
  • 22 Tan R, Santiago D. Clinical features, Treatment and Outcomes of Retinoblastoma patients in India, China, Pakistan, Indonesia, Bangladesh and the Philippines. Philippines; 2019. (Unpublished)
  • 23 Bai S, Ren R, Li B. et al. Delay in the diagnosis of retinoblastoma in China. Acta Ophthalmol 2011; 89 (01) e72-e74
  • 24 Gao YJ, Qian J, Yue H, Yuan YF, Xue K, Yao YQ. Clinical characteristics and treatment outcome of children with intraocular retinoblastoma: a report from a Chinese cooperative group. Pediatr Blood Cancer 2011; 57 (07) 1113-1116
  • 25 Gao J, Zeng J, Guo B. et al. Clinical presentation and treatment outcome of retinoblastoma in children of South Western China. Medicine (Baltimore) 2016; 95 (42) e5204
  • 26 Huang D, Zhang Y, Zhang W. et al. Study on clinical therapeutic effect including symptoms, eye preservation rate, and follow-up of 684 children with retinoblastoma. Eur J Ophthalmol 2013; 23 (04) 532-538